VivoSim Labs, Inc. (VIVS) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) is a pharmaceutical and biotechnology services company focused on providing drug testing using 3D human tissue models of the liver and intestine. In March 2025, the company sold its FXR314 drug program for $10.0 million (with potential milestones up to $50.0 million) and shifted its primary focus to a services model offering toxicology insights and bespoke research services. The company operates as a single segment: Research & Development.
Key Financial Metrics
| Metric | Six Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2024 |
|---|---|---|
| Total Revenue | $65,000 | $69,000 |
| Net Loss | $(5,388,000) | $(5,893,000) |
| Operating Loss | $(5,550,000) | $(5,994,000) |
| Cash and Cash Equivalents (as of Sept 30, 2025) | $6,677,000 | N/A |
| Working Capital (as of Sept 30, 2025) | $5,200,000 | N/A |
| Accumulated Deficit (as of Sept 30, 2025) | $(347,545,000) | N/A |
| Net Cash Used in Operating Activities | $(6,318,000) | $(5,625,000) |
Note: All figures in thousands except per share data. Revenue consists primarily of royalty revenue ($65,000) from licensing agreements. Product revenue was $0 as the Mosaic division ceased operations.
Material Changes vs. Prior Period
- Revenue: Total revenue decreased slightly by 6% ($4,000) compared to the prior six-month period, driven by the cessation of product revenue from the former Mosaic division, partially offset by a 23% increase in royalty revenue.
- Expenses: Research and Development (R&D) expenses decreased by 19% ($462,000) due to a reduction in headcount (from 14 to 9 average full-time employees) and lower stock-based compensation. Selling, General, and Administrative (SG&A) expenses remained relatively flat, increasing only 0.5% ($17,000), despite a decrease in personnel costs, due to increased consulting fees for the new service model.
- Liquidity: Cash and cash equivalents decreased by approximately $4.6 million during the period, primarily due to operating cash outflows of $6.3 million, partially offset by $1.8 million in net proceeds from At-The-Market (ATM) stock offerings.
- Capital Structure: The company issued 701,729 shares of common stock via ATM offerings during the six months ended September 30, 2025.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year following the issuance date. The company expects to incur substantial additional operating losses and will require significant additional funding to support operations.
- Guidance: The company expects total operating expenses for the fiscal year ending March 31, 2026, to be between $10 million and $12 million. It anticipates R&D expenses to decrease while service revenue increases as the new business model executes.
- Strategic Focus: The company is advancing a "Preclinical IBD Program" with a goal of filing an Investigational New Drug (IND) application by December 2026. It is also leveraging its liver toxicology platform, which demonstrated 87.5% sensitivity and 100% specificity in recent testing.
- Legal Contingencies: The company is involved in litigation with H.C. Wainwright & Co., LLC regarding a tail financing provision. An accrual of $0.6 million has been recognized for this loss contingency.
- Regulatory Risks: The filing notes potential disruptions to FDA and SEC operations due to the U.S. federal government shutdown that began October 1, 2025, which could delay regulatory reviews and financing activities.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $6.7 million cash balance against the projected $10-$12 million annual operating expense burn rate.
- Financing Capability: Confirm the availability of the remaining $3.1 million under the ATM program and the impact of the "public float" limitation (one-third of public float) on future capital raises.
- FXR Milestones: Monitor the status of the FXR314 asset sale to Eli Lilly and Company to determine if any of the potential $50 million in milestone payments are becoming probable.
- Legal Exposure: Track the resolution of the H.C. Wainwright litigation and the potential for additional legal costs or damages beyond the current $0.6 million accrual.
- Service Revenue Growth: Assess the actual uptake of the new toxicology screening services to validate the management's expectation of increasing service revenue.